Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00385736 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis

A Phase 3 study, sponsored by Abbott.

Completed
Registry status
Phase 3
Development phase
576
Enrollment target

NCT00385736: Completed Phase 3 study, sponsored by Abbott.

NCT00385736 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 576 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00385736, a Phase 3 study, has completed, sponsored by Abbott.

COMPLETED
Registry status
Phase 3
Development phase
576 participants
Enrollment target

Study Summary

The objective of this study is to assess the efficacy and safety of adalimumab for the induction of clinical remission in subjects with moderately to severely active ulcerative colitis.

Primary Outcome

Clinical remission per Mayo score is defined as a total Mayo score \<= 2 and no individual subscore \> 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, Endoscopy Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

Interventions

  • BIOLOGICAL placebo
  • BIOLOGICAL adalimumab

Trial Details

FieldValue
Enrollment Target 576 participants
Start Date 2006-11
Est. Completion 2010-03
Phase Phase 3
Abbott

181 total trials

What the finished NCT00385736 record still lists

NCT00385736 is an interventional study that assigns participants to a tested intervention. The registered 576 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% lower).

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT00385736 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00385736 about?

NCT00385736 is a clinical study titled "Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis". The objective of this study is to assess the efficacy and safety of adalimumab for the induction of clinical remission in subjects with moderately to severely active ulcerative colitis.

What is the current status of trial NCT00385736?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 576 participants. The study started on 2006-11. Estimated completion is 2010-03.

What interventions are being tested in trial NCT00385736?

The interventions under investigation include: placebo (BIOLOGICAL), adalimumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00385736?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00385736's enrollment target sits among peer trials

576 661st of 2000 higher than 1,340 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04931810 · 576 participants · NA

    Urban and Reservation Implementation of All Nations Breath of Life

  • NCT05179369 · 576 participants · NA

    Well-Mama Community Doula Navigator Study

  • NCT06398509 · 576 participants · NA

    A Primary Care Based Intervention to Prevent Childhood Obesity Among Low-income Latino Children

  • NCT02610439 · 575 participants

    Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00385736, the US trial registry maintained by the National Library of Medicine. NCT00385736 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.